Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.
about
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human diseasecGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical TrialsAngiogenesis: a harmonized target for recovery after stroke.Endothelial actions of atrial and B-type natriuretic peptidesSuppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10.OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer TherapiesNexavar/Stivarga and viagra interact to kill tumor cells.GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction.Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase.COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling.
P2860
Q28254667-B1735F5C-5107-4321-8B0C-D6D86DDDD4C7Q34244951-3A7D36DB-2BAE-4DBF-A9D2-641D0BA80BC0Q34289307-E52079F4-BB3F-494F-9982-9E47F52D0898Q34357737-043B2278-7DD6-4846-9084-AECD83912455Q35550902-46C0E305-3EF9-4060-8042-1FFFA9733B48Q36113683-6C24296C-BBAB-4DAE-B0BA-806F944331D1Q36159149-6662E7BA-9608-4BB0-8606-87805E7F510DQ36413785-16C08225-0A79-4213-8599-E3F697CB5510Q36808317-79A7961A-F2DF-4906-9B4A-93A4CADF4855Q36808335-0AA45F41-D3A3-46AA-BA21-A9D726D19A32Q36830763-63287B9A-4D0E-4AC1-9BCC-54A3A707A79EQ37162500-13CE1227-FDB8-4B2A-A83B-F89A0FA4AE58Q37629029-49AC1F52-88D9-4942-82B5-8ABA8EB9648AQ38123175-CED1B86C-4875-465E-9B53-8370CC9AE51EQ38166600-76DDF1AC-2ECA-44D1-B6E5-98CB5B30FC23Q42378330-88B691B6-6F8F-479D-AF7E-26D6E006D478
P2860
Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@ast
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@en
type
label
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@ast
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@en
prefLabel
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@ast
Type 5 phosphodiesterase expre ...... ial cell angiogenic phenotype.
@en
P2093
P2860
P1476
Type 5 phosphodiesterase expre ...... lial cell angiogenic phenotype
@en
P2093
Mikhail Alexeyev
Samuel J Strada
Troy Stevens
P2860
P304
P356
10.1152/AJPLUNG.90474.2008
P577
2008-11-21T00:00:00Z